<DOC>
	<DOCNO>NCT02638948</DOCNO>
	<brief_summary>The purpose study determine whether study drug , BMS-986142 , safe effective treat moderate severe rheumatoid arthritis subject inadequate response methotrexate methotrexate 2 tumour necrosis factor ( TNF ) Inhibitors . Patients qualify randomize either one 3 dos BMS-986142 placebo 1:1:1:1 randomization 12 week . Disease activity safety assess course study .</brief_summary>
	<brief_title>Efficacy Safety Study BMS-986142 Patients With Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Male female age 18 Diagnosed active rheumatoid arthritis ( RA ) standard criterion least 16 week screen , functional ACR class IIII Have inadequate response methotrexate In addition inadequate response methotrexate inadequate response intolerance 1 2 TNF inhibitor Have minimum 6 swollen 6 tender joint ( 66/68 joint count ) Have hsCRP ≥ 0.8 mg/dL ( 8mg/L ) [ central laboratory value ] ESR ≥ 28 mm/hr Willing use effective birth control entire length study Diagnosed juvenile Rheumatoid Arthritis Have treat biologic treatment TNF inhibitor Active systemic bacterial , viral fungal infection evidence prior current Hepatitis B C infection HIV infection , latent bacterial , viral fungal infection Have treat Intramuscular Intraarticular glucocorticosteroids within 4 week randomization Taking Oral steroid dose 10 mg/day prednisone ( prednisone equivalent ) Have autoimmune disease RA like lupus , multiple sclerosis Have significant concurrent medical condition time screen baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>